Biotechnology - Pharmaceutical, Immunologicals

Filter

Popular Filters

Novartis enters into a collaboration for Il-17 inhibitor

06-08-2013

US biotech firm Ensemble Therapeutics, a company developing Ensemblins, a novel class of small molecule…

BiotechnologyEnsemble TherapeuticsImmunologicalsInflammatory diseasesLicensingNovartisPharmaceutical

Teijin and Amgen join forces on autoimmune disease research

31-07-2013

Japan's Teijin Pharma, the core company of the Teijin Group's (TSE: 3401) health care business, has entered…

AmgenBiotechnologyImmunologicalsInflammatory diseasesLicensingPharmaceuticalResearchTeijin

Merck Serono sets up new platform for cancer therapies innovation

26-06-2013

Merck Serono, the biopharmaceutical division of Germany's Merck KGaA (MRK: DE) says it has created a…

BiotechnologyImmunologicalsMerck KGaAMerck SeronoOncologyPharmaceuticalResearch

Lupus therapeutics boast blockbuster hopefuls as R&D continues, says GlobalData

24-06-2013

Lupus therapeutics are lacking, and patients with moderate forms of the disease are greatly underserved,…

BenlystaBiotechnologyBristol-Myers SquibbepratuzumabGlaxoSmithKlineImmunologicalsMarkets & MarketingOrenciaPharmaceuticalRare diseasesResearchUCB

Additional indications in Japan for Roche's Avastin and Astellas' Prograf

17-06-2013

Swiss drug major Roche (ROG: SIX) says that the Japanese Ministry of Health, Labor and Welfare (MHLW)…

Asia-PacificAstellas PharmaAvastinBiotechnologyImmunologicalsOncologyPharmaceuticalPrografRegulationRoche

Baxter and Halozyme's HyQvia approved in European Union

22-05-2013

USA-based Baxter International (NYSE: BAX) and Halozyme Therapeutics (Nasdaq: HALO) say that the European…

BaxterBiotechnologyEuropeHalozyme TherapeuticsHyQviaImmunologicalsPharmaceuticalRegulation

US FDA accepts Merck & Co's BLA ragweed pollen allergy immunotherapy

09-05-2013

US pharma giant Merck & Co (NYSE: MRK) revealed yesterday (May 8) that the Biologics License Application…

Alk-AbelloBiotechnologyImmunologicalsMerck & CoNorth AmericaPharmaceuticalRegulation

Sanofi and Transgene collaborate on immunotherapy treatments; NAS designation of Aubagio disputed

25-03-2013

Drug major Sanofi (Euronext: SAN) and fellow France-based biotech firm Transgene SA (NYSE-Euronext: TNG)…

AubagioBiotechnologyEuropeGenzymeImmunologicalsNeurologicalPharmaceuticalProductionRegulationSanofiTransgene

Positive NICE news for GSK's Revolade and InterMune's Esbriet

21-03-2013

UK drugs watchdog the National Institute for Health and Clinical Excellence today (March 21) issued two…

BiotechnologyEsbrietEuropeGlaxoSmithKlineImmunologicalsInterMunePharmaceuticalPricingRegulationRespiratory and PulmonaryRevolade

FDA advisory gives negative opinion on Hemispherx' Ampligen

27-12-2012

The Arthritis Advisory Committee (AAC) of the US Food and Drug Administration last week voted against…

AmpligenBiotechnologyHemispherx BioPharmaImmunologicalsNorth AmericaPharmaceuticalRegulation

Sanofi inks up to $900 million allergy pact with Selecta Biosciences

28-11-2012

US clinical-stage biopharma company Selecta Biosciences revealed this morning that it has entered into…

BiotechnologyImmunologicalsLicensingPharmaceuticalResearchSanofiSelecta BiosciencesVaccines

European therapeutic MAbs market to reach over $42 billion in 2018, says F&S

10-10-2012

Efficient resource to therapy of complex disorders with lesser side effects has accelerated growth of…

BiotechnologyImmunologicalsInflammatory diseasesMarkets & MarketingOncologyPharmaceuticalResearch

Osiris regains worldwide rights to Prochymal and Chondrogen from Sanofi

30-09-2012

As a result of the termination of its collaboration with Genzyme, a subsidiary of French drug major Sanofi…

BiotechnologyChondrogenGenzymeImmunologicalsInflammatory diseasesLicensingOsiris TherapeuticsPharmaceuticalProchymalSanofi

Abbott/Eisai's Humira has emerged as leading psoriasis agent

07-08-2012

For the treatment of psoriasis, Abbott/Eisai's Humira (adalimumab) has displaced Amgen/Stiefel/Pfizer/Takeda's…

Abbott LaboratoriesAmgenAnti-Arthritics/RheumaticsBiotechnologyEisaiEnbrelGlobalHumiraImmunologicalsJanssenMarkets & MarketingPfizerPharmaceuticalStelara Injection

Barriers to overcome in lupus drug development

22-07-2012

It has taken the lupus research community over 50 years to produce a new therapy. Although it is now…

Anthera PharmaceuticalsBenlystaBiotechnologyblisibimodGlaxoSmithKlineImmunologicalsPharmaceuticalResearch

GlaxoSmithKline links with Japan's Chiome on MAbs

10-04-2012

UK pharma giant GlaxoSmithKline group (LSE: GSK) and Tokyo, Japan-based biotech-venture company Chiome…

BiotechnologyChiome BioscienceGlaxoSmithKlineImmunologicalsLicensingOncologyPharmaceuticalResearch

Ablynx extends Nanobody deal with Boehringer

21-03-2012

Belgian drug developer Ablynx (Euronext Brussels: ABLX) yesterday announced a two-year extension of the…

AblynxBiotechnologyBoehringer IngelheimImmunologicalsLicensingOncologyPharmaceuticalRespiratory and Pulmonary

Ablynx earns milestone from Merck Serono

13-12-2011

Belgium’s Ablynx (Euronext Brussels: ABLX) says it will earn a 1 million-euro ($1.3 million) from…

AblynxBiotechnologyFinancialImmunologicalsMerck KGaAMerck SeronoPharmaceuticalResearch

Early treatment with Biogen and Elan’s Tysabri reduces MS relapse rates

19-10-2011

US biotech firm Biogen Idec (Nasdaq: BIIB) and Ireland-based Elan Corp (NYSE: ELN) have released new…

Biogen IdecBiotechnologyElanImmunologicalsNeurologicalPharmaceuticalResearchTysabri

Merck KGaA has another stab at multiple sclerosis, gaining rights to Peptimmune PI-2301 program

19-09-2011

German drug major Merck KGaA (MRK: DE) is taking another look at the multiple sclerosis market, where…

BiotechnologyImmunologicalsLicensingMerck KGaANeurologicalPeptimmunePharmaceutical

Back to top